All In Biotech

Drug Trial Radar · NCT07925021

A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma

A Randomized, Open-label, Multicenter Phase Ⅲ Trial to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart Injection Versus Tislelizumab Combined With Chemotherapy (Gemcitabine Plus Cisplatin) in Patients With Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

424

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Oct 1, 2029

Study completion Dec 1, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multicenter phase Ⅲ trial to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart injection versus Tislelizumab combined with chemotherapy (gemcitabine plus cisplatin) in patients with previously systemic treatment-naive recurrent or metastatic nasopharyngeal carcinoma

Conditions

  • Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

  • SYS6010 combined with EnlonstobartDrug

    Participants in the experimental group will receive SYS6010, administered on Day 1 of each cycle. Participants in the experimental group will receive Enlonstobart, administered on Day 1 of each cycle.

  • Tislelizumab combined with chemotherapyDrug

    Participants in the control group will receive: Tislelizumab :200 mg, administered by intravenous infusion on D1 every 21-day treatment cycle; Gemcitabine: 1000 mg/m², administered by intravenous infusion on D1 and 8 of each 21-day cycle; Cisplatin: 80 mg/m², administered by intravenous infusion on D1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival by Blinded Independent Central Review (BICR) based on RECIST v1.1.Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 37 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.